$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx

$aldx Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-Q Financial Statement

#000119312514233411 Filed on June 11, 2014

Income Statement

Concept	2014 Q1	2013 Q1	2012
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$800.0K	$140.0K	$640.0K
YoY Change	471.43%		-13.51%
% of Gross Profit
Research & Development	$444.3K	$150.2K	$470.0K
YoY Change	195.73%		-65.44%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$444.3K	$150.2K	$1.120M
YoY Change	195.73%		-46.92%
Operating Profit	-$1.245M	-$291.5K
YoY Change	327.02%
Interest Expense	$113.2K	$15.40K	-$480.0K
YoY Change	635.06%		77.78%
% of Operating Profit
Other Income/Expense, Net	$1.647M	-$3.683M	$0.00
YoY Change	-144.71%		-100.0%
Pretax Income	$400.0K	-$3.970M	-$23.07M
YoY Change	-110.08%		869.33%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	$401.8K	-$3.975M	-$23.07M
YoY Change	-110.11%		870.31%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.04	-$13.03
Diluted Earnings Per Share	-$4.04	-$13.03	-$3.691M
COMMON SHARES
Basic Shares Outstanding	327.4K shares	314.4K shares
Diluted Shares Outstanding	439.0K shares	314.4K shares

Balance Sheet

Concept	2014 Q1	2013 Q1	2012
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.100M		$1.220M
YoY Change			388.0%
Cash & Equivalents	$2.146M	$1.676M	$1.220M
Short-Term Investments
Other Short-Term Assets	$0.00		$0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$2.155M		$1.980M
YoY Change			661.54%
LONG-TERM ASSETS
Property, Plant & Equipment			$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$700.0K		$0.00
YoY Change
Total Long-Term Assets	$735.2K		$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$2.155M		$1.980M
Total Long-Term Assets	$735.2K		$0.00
Total Assets	$2.891M		$1.980M
YoY Change			661.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$166.0K		$70.00K
YoY Change			133.33%
Accrued Expenses	$133.1K		$120.0K
YoY Change			-67.57%
Deferred Revenue
YoY Change
Short-Term Debt	$200.0K		$0.00
YoY Change			-100.0%
Long-Term Debt Due	$232.6K		$170.0K
YoY Change
Total Short-Term Liabilities	$691.5K		$360.0K
YoY Change			-86.1%
LONG-TERM LIABILITIES
Long-Term Debt	$972.4K		$26.77M
YoY Change
Other Long-Term Liabilities	$600.0K		$0.00
YoY Change
Total Long-Term Liabilities	$972.4K		$26.77M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$691.5K		$360.0K
Total Long-Term Liabilities	$972.4K		$26.77M
Total Liabilities	$4.027M		$27.13M
YoY Change			947.49%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$39.65M		-$25.15M
YoY Change
Total Liabilities & Shareholders Equity	$2.891M		$1.980M
YoY Change			661.54%

Cashflow Statement

Concept	2014 Q1	2013 Q1	2012
OPERATING ACTIVITIES
Net Income	$401.8K	-$3.975M	-$23.07M
YoY Change	-110.11%		870.31%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$1.060M	-$300.0K	-$780.0K
YoY Change	253.33%		-67.36%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-50.00K	750.0K	1.750M
YoY Change	-106.67%
NET CHANGE
Cash From Operating Activities	-1.060M	-300.0K	-780.0K
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	-50.00K	750.0K	1.750M
Net Change In Cash	-1.110M	450.0K	970.0K
YoY Change	-346.67%		-140.59%
FREE CASH FLOW
Cash From Operating Activities	-$1.060M	-$300.0K	-$780.0K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$1.060M	-$300.0K	-$780.0K
YoY Change	253.33%		-67.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2010Q1	aldx	Aggregate Development And Regulatory Milestone Payments To Licensor AggregateDevelopmentAndRegulatoryMilestonePaymentsToLicensor	2150000
CY2013Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.06	pure
CY2013Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	170000
CY2013Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	177952
CY2012Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	88100
CY2012Q2	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	500000
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5565413	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	106285	shares
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1676053
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	232640
CY2014Q1	us-gaap	Assets Current AssetsCurrent	2155362
CY2014Q1	us-gaap	Assets Assets	2890566
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2145621
CY2014Q1	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	40922565
CY2014Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	190774
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9741
CY2014Q1	aldx	Percentage Of Voting Rights Interest PercentageOfVotingRightsInterest	0.67	pure
CY2014Q1	aldx	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	735204
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.48
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	609842	shares
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	133071
CY2014Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	972418
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1276803
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	165961
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	691501
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-39645435
CY2014Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	38508866
CY2014Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	132373
CY2014Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	155097
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2890566
CY2014Q1	us-gaap	Liabilities Liabilities	4027135
CY2014Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1758952
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q1	aldx	Accrued Deferred Offering Costs AccruedDeferredOfferingCosts	604264
CY2014Q1	aldx	Cash Reserve For Indemnities And Guarantees CashReserveForIndemnitiesAndGuarantees	0
CY2014Q1	aldx	Related Party Transaction Derivative Liability Noncurrent RelatedPartyTransactionDerivativeLiabilityNoncurrent	1626579
CY2014Q1	aldx	Indemnification Obligations Claims Outstanding IndemnificationObligationsClaimsOutstanding	0
CY2014Q1	aldx	Accrued Interest On Convertible Notes Payable Related Parties AccruedInterestOnConvertibleNotesPayableRelatedParties	4732
CY2004Q4	us-gaap	Stockholders Equity StockholdersEquity	947
CY2004Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2005Q4	us-gaap	Stockholders Equity StockholdersEquity	-385213
CY2006Q4	us-gaap	Stockholders Equity StockholdersEquity	-1324189
CY2007Q4	us-gaap	Stockholders Equity StockholdersEquity	-1847171
CY2008Q4	us-gaap	Stockholders Equity StockholdersEquity	-4057955
CY2008Q4	us-gaap	Common Stock Value CommonStockValue	90864
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	-9210595
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	-12969489
CY2010Q4	us-gaap	Common Stock Value CommonStockValue	373
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-15512997
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-54384496
CY2012Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	500000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.48
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1223638
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	609842	shares
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	117873
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1129015
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1102685
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	341853
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	605011
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-40221326
CY2013Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	38317298
CY2013Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	253247
CY2013Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	85000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3743233
CY2013Q4	us-gaap	Liabilities Liabilities	5647261
CY2013Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3518867
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	58160
CY2013Q4	us-gaap	Assets Current AssetsCurrent	3270766
CY2013Q4	us-gaap	Assets Assets	3743233
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3262354
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	41324338
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8412
CY2013Q4	aldx	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	472467
CY2013Q4	aldx	Accrued Deferred Offering Costs AccruedDeferredOfferingCosts	394368
CY2013Q4	aldx	Related Party Transaction Derivative Liability Noncurrent RelatedPartyTransactionDerivativeLiabilityNoncurrent	3265620
CY2013Q4	aldx	Accrued Interest On Convertible Notes Payable Related Parties AccruedInterestOnConvertibleNotesPayableRelatedParties	2125
	us-gaap	Net Income Loss NetIncomeLoss	-2322
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	269
CY2013Q4	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.0650	pure
CY2013Q4	us-gaap	Line Of Credit Facility Annual Principal Payment LineOfCreditFacilityAnnualPrincipalPayment	58160
CY2012Q2	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.0275	pure
CY2012Q2	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.0650	pure
CY2012Q2	aldx	Penalty For Early Payment Of Principal PenaltyForEarlyPaymentOfPrincipal	0
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-17443299
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9741
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-53772497
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	104167
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	250756
	us-gaap	Income Taxes Paid IncomeTaxesPaid
	us-gaap	Investment Income Interest InvestmentIncomeInterest	188741
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20451923
	us-gaap	Interest Paid InterestPaid	293862
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4179017
	us-gaap	Net Income Loss NetIncomeLoss	-24630940
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7942
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2471700
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	2128205
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	42566
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7160496
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	19596862
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5130000
	us-gaap	Share Based Compensation ShareBasedCompensation	2371865
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2145621
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-7942
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	133071
	us-gaap	Interest Expense InterestExpense	1102372
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	165961
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3773
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13291427
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6435
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1500000
	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	11351454
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	15661898
	us-gaap	Depreciation Depreciation	7942
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2371865
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	230374
	aldx	Deferred Offering Costs Not Yet Paid DeferredOfferingCostsNotYetPaid	604264
	aldx	Conversion Of Notes Payable To Redeemable Convertible Preferred Stock ConversionOfNotesPayableToRedeemableConvertiblePreferredStock	2793474
	aldx	Increase Decrease In Accrued Interest On Notes Payable IncreaseDecreaseInAccruedInterestOnNotesPayable	4732
	aldx	Excess Of Fair Value Over Share Issue Price ExcessOfFairValueOverShareIssuePrice	21484762
	aldx	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	2128205
	aldx	Proceeds From Issuance Of Restricted Common Stock ProceedsFromIssuanceOfRestrictedCommonStock	7147
	aldx	Conversion Of Accrued Interest To Convertible Preferred Stock ConversionOfAccruedInterestToConvertiblePreferredStock	593473
	aldx	President And Ceo Contributed Services PresidentAndCeoContributedServices	216388
	aldx	Change In Fair Value Of Warrant Liabilities Purchase Right And Warrant Purchase Rights ChangeInFairValueOfWarrantLiabilitiesPurchaseRightAndWarrantPurchaseRights	-18011186
	aldx	Deferred Offering Costs Paid By Cash DeferredOfferingCostsPaidByCash	130940
	aldx	Fair Value Of Warrants Issued In Connection With Credit Facility FairValueOfWarrantsIssuedInConnectionWithCreditFacility	266052
	aldx	Fair Value Of Warrants Issued In Connection With Redeemable Convertible Preferred Stock FairValueOfWarrantsIssuedInConnectionWithRedeemableConvertiblePreferredStock	26279400
	aldx	Offeratory Costs In Connection With Redeemable Convertible Preferred Stock Issuance Included In Accrued Expenses OfferatoryCostsInConnectionWithRedeemableConvertiblePreferredStockIssuanceIncludedInAccruedExpenses	62950
	aldx	Conversion Of Bridge Loans To Preferred Stock ConversionOfBridgeLoansToPreferredStock	2960649
	aldx	Exercise Of Warrant Purchase Rights Into Warrants ExerciseOfWarrantPurchaseRightsIntoWarrants	1793600
	aldx	Allocation Of Fair Value Of Investor Purchase Rights To Redeemable Convertible Preferred Stock AllocationOfFairValueOfInvestorPurchaseRightsToRedeemableConvertiblePreferredStock	9047714
	aldx	Fair Value Adjustment Of Convertible Preferred Stock Rights And Rights Option Liabilities FairValueAdjustmentOfConvertiblePreferredStockRightsAndRightsOptionLiabilities	15539486
CY2005	us-gaap	Net Income Loss NetIncomeLoss	-386454
CY2005	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	294
CY2006	us-gaap	Net Income Loss NetIncomeLoss	-939026
CY2006	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50
CY2007	us-gaap	Net Income Loss NetIncomeLoss	-523032
CY2007	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-4975228
CY2009	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23638
CY2009	aldx	Accretion Of Discounts And Issuance Costs On Preferred Stock AccretionOfDiscountsAndIssuanceCostsOnPreferredStock	201050
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-3590169
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40206
CY2010	aldx	Accretion Of Discounts And Issuance Costs On Preferred Stock AccretionOfDiscountsAndIssuanceCostsOnPreferredStock	209304
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-2378064
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49592
CY2011	aldx	Accretion Of Discounts And Issuance Costs On Preferred Stock AccretionOfDiscountsAndIssuanceCostsOnPreferredStock	215036
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	7147
CY2013	us-gaap	Net Income Loss NetIncomeLoss	13060472
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	170000
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1701713
CY2013	aldx	Accretion Of Discounts And Issuance Costs On Preferred Stock AccretionOfDiscountsAndIssuanceCostsOnPreferredStock	822550
CY2013	aldx	Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Value To President And Ceo AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValueToPresidentAndCeo	46388
CY2008	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6500
CY2008	us-gaap	Net Income Loss NetIncomeLoss	-2224375
CY2008	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15437
CY2008	aldx	Accretion Of Discounts And Issuance Costs On Preferred Stock AccretionOfDiscountsAndIssuanceCostsOnPreferredStock	99210
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-23074515
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	84401
CY2012	us-gaap	Line Of Credit Facility Periodic Payment Principal LineOfCreditFacilityPeriodicPaymentPrincipal	20833
CY2012	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	15700000
CY2012	aldx	Deemed Dividend On Preferred Stock DeemedDividendOnPreferredStock	15661898
CY2012	aldx	Line Of Credit Facility Date Of Last Required Payment LineOfCreditFacilityDateOfLastRequiredPayment	2013-04-12
CY2012	aldx	Accretion Of Discounts And Issuance Costs On Preferred Stock AccretionOfDiscountsAndIssuanceCostsOnPreferredStock	389487
CY2012	aldx	Number Of Advance Payments Received NumberOfAdvancePaymentsReceived	2	Payments
CY2012	aldx	Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Value To President And Ceo AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValueToPresidentAndCeo	170000
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-13.03
CY2013Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	314419	shares
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.03
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-298021
CY2013Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	314419	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3236826	shares
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9423
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4098092
CY2013Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	8
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4098092
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-291538
CY2013Q1	us-gaap	Interest Paid InterestPaid	8125
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3683395
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-3974933
CY2013Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	277500
CY2013Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	123159
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	141305
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001341235
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	750436
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	50447
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	452415
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-20032
CY2013Q1	us-gaap	Interest Expense InterestExpense	15403
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-61915
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	150233
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50447
CY2013Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	7335
CY2013Q1	aldx	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	123159
CY2013Q1	aldx	Contributed Service Fees ContributedServiceFees	42500
CY2013Q1	aldx	President And Ceo Contributed Services PresidentAndCeoContributedServices	42500
CY2013Q1	aldx	Change In Fair Value Of Warrant Liabilities Purchase Right And Warrant Purchase Rights ChangeInFairValueOfWarrantLiabilitiesPurchaseRightAndWarrantPurchaseRights	3668000
CY2013Q1	aldx	Fair Value Adjustment Of Convertible Preferred Stock Rights And Rights Option Liabilities FairValueAdjustmentOfConvertiblePreferredStockRightsAndRightsOptionLiabilities	-3390500
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	ALDEYRA THERAPEUTICS, INC.
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	Each share of Voting Preferred Stock and each share of Non-Voting Preferred Stock was convertible into one share of the same such series of Non-Voting Preferred Stock or one share of the same such series of Voting Preferred Stock without the payment of any additional consideration by the holder.
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.00
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	443826	shares
CY2014Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	111610	shares
CY2014Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	One-for-twelve
CY2014Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>2.</b></td> <td valign="top" align="left"><b>BASIS OF PRESENTATION</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The accompanying interim unaudited financial statements and related disclosures are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s financial statements for the year ended December 31, 2013 included in the Company’s Registration Statement on Form S-1, as amended (File No. 333-193204) (Registration Statement), which was declared effective by the Securities and Exchange Commission (SEC) on May 1, 2014. The financial information as of March 31, 2014, the three months ended March 31, 2014 and 2013 and the cumulative period from August 13, 2004 (Inception) to March 31, 2014 is unaudited but, in the opinion of management, all adjustments, consisting only of normal recurring accruals, considered necessary for a fair statement of the results of these interim periods have been included. The balance sheet data as of December 31, 2013 was derived from audited financial statements. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company’s initial public offering of common stock (Initial Public Offering) was completed on May 7, 2014.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Reverse stock split</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> On January 23, 2014, the Company’s board of directors and stockholders approved an amendment to the restated certificate of incorporation to effect a one-for-twelve reverse stock split of the Company’s common stock, options for common stock, convertible preferred stock, and warrants for convertible preferred stock which became effective on May 1, 2014, prior to the effectiveness of the Registration Statement (the Reverse Stock Split). The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock, options for common stock, convertible preferred stock, and rights and warrants for convertible preferred stock, as well as the exercise price of each option for common stock, each right and each warrant for convertible preferred stock, and each right for warrants for convertible preferred stock and the conversion price for convertible preferred stock, have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. All of the share and per share amounts have been adjusted, on a retroactive basis, to reflect the Reverse Stock Split.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b><i>Development Stage Operations</i></b> – The Company’s executive personnel have devoted substantially all of their time to date to the planning and organization of the Company, the process of initiating research and development programs, and securing adequate capital for anticipated growth and operations. The Company is subject to a number of risks, including, but not limited to, the need to raise capital through equity and/or debt financings; the uncertainty of whether the Company’s research and development efforts will result in successful commercial products; competition from larger organizations; dependence on key personnel and uncertain patent protection. The Company is in its development stage as defined by the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 915, <i>Development Stage Entities</i>.</p> </div>
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2014Q1	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>NATURE OF BUSINESS</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> Aldeyra Therapeutics, Inc. (the Company) was incorporated in the state of Delaware on August 13, 2004 as Neuron Systems, Inc. On December 20, 2012, the Company changed its name to Aldexa Therapeutics, Inc. and on March 17, 2014 the Company changed its name to Aldeyra Therapeutics, Inc. The Company is developing a treatment for diseases related to high levels of free aldehydes, naturally occurring pro-inflammatory toxins.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> The Company’s principal activities to date include raising capital and research and development activities.</p> </div>
CY2014Q1	us-gaap	Preferred Stock Redemption Date PreferredStockRedemptionDate	2015-06-23
CY2014Q1	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2015-04-13
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M5D
CY2014Q1	us-gaap	Line Of Credit Facility Interest Rate Description LineOfCreditFacilityInterestRateDescription	To provide additional capital for general working capital purposes and for capital expenditures. Interest accrued from the date of each advance equal to the greater of (a) 2.75% above the prime rate then in effect per annum, or (b) 6.50% per annum.
CY2014Q1	us-gaap	Line Of Credit Facility Initiation Date1 LineOfCreditFacilityInitiationDate1	2013-05-12
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1063892
CY2014Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	4851	shares
CY2014Q1	us-gaap	Line Of Credit Facility Frequency Of Payments LineOfCreditFacilityFrequencyOfPayments	24 equal monthly installments
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	327365	shares
CY2014Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1759915
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y11M9D
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	307377	shares
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2014Q1	us-gaap	Other Commitments Description OtherCommitmentsDescription	During the period from January 6, 2012 through October 14, 2013, he was not paid a salary by the Company and was an employee and paid a salary by Domain Associates, LLC (Domain), a related party. The value of his services has been reflected in the statement of operations as an expense and recorded as a contribution of capital.
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1329
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13237
CY2014Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1773152
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1244924
CY2014Q1	us-gaap	Interest Paid InterestPaid	22682
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1646697
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	401773
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	365686
CY2014Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	0
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1759915
CY2014Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	191568
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	800646
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-52841
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	365686
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1116733
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	15198
CY2014Q1	us-gaap	Interest Expense InterestExpense	113221
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-175892
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	444278
CY2014Q1	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	223442
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	365686
CY2014Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	87980
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2014Q1	aldx	Deferred Offering Costs Not Yet Paid DeferredOfferingCostsNotYetPaid	209896
CY2014Q1	aldx	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1.00	pure
CY2014Q1	aldx	Increase Decrease In Accrued Interest On Notes Payable IncreaseDecreaseInAccruedInterestOnNotesPayable	2607
CY2014Q1	aldx	Lines Of Credit Facility Maturity Period LinesOfCreditFacilityMaturityPeriod	2016-11
CY2014Q1	aldx	Number Of Incentive Plans NumberOfIncentivePlans	3	Incentive_Plan
CY2014Q1	aldx	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	191568
CY2014Q1	aldx	Deferred Offering Costs Paid By Cash DeferredOfferingCostsPaidByCash	52841
CY2014Q1	aldx	Change In Fair Value Of Warrant Liabilities Purchase Right And Warrant Purchase Rights ChangeInFairValueOfWarrantLiabilitiesPurchaseRightAndWarrantPurchaseRights	-1759915
CY2014Q1	aldx	License Agreement Termination Description LicenseAgreementTerminationDescription	The license and supply agreement runs through the 7th anniversary of the expiration of all patents licensed under the agreement, which the Company estimates to be April 2036, unless terminated earlier.
CY2014Q1	aldx	Initial Public Offering Date Of Completion InitialPublicOfferingDateOfCompletion	2014-05-07
CY2014Q1	aldx	Interest Payment Period For Line Of Credit Facility InterestPaymentPeriodForLineOfCreditFacility	November 2013 through November 2014
CY2014Q1	aldx	Contributed Service Fees ContributedServiceFees	0
CY2014Q1	aldx	Accretion Of Discounts And Issuance Costs On Preferred Stock AccretionOfDiscountsAndIssuanceCostsOnPreferredStock	191568

Files In Submission

Name	View Source	Status
0001193125-14-233411-index-headers.html	Edgar Link	pending
0001193125-14-233411-index.html	Edgar Link	pending
0001193125-14-233411.txt	Edgar Link	pending
0001193125-14-233411-xbrl.zip	Edgar Link	pending
aldx-20140331.xml	Edgar Link	completed
aldx-20140331.xsd	Edgar Link	pending
aldx-20140331_cal.xml	Edgar Link	unprocessable
aldx-20140331_def.xml	Edgar Link	unprocessable
aldx-20140331_lab.xml	Edgar Link	unprocessable
aldx-20140331_pre.xml	Edgar Link	unprocessable
d726934d10q.htm	Edgar Link	pending
d726934dex311.htm	Edgar Link	pending
d726934dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx

2014 Q1 Form 10-Q Financial Statement

#000119312514233411 Filed on June 11, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALDX Aldeyra Therapeutics, Inc. Stock $aldx

2014 Q1 Form 10-Q Financial Statement

#000119312514233411 Filed on June 11, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx